Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Lassen U, et al. Among authors: nielsen dl. Cancer Chemother Pharmacol. 2013 Feb;71(2):543-9. doi: 10.1007/s00280-012-2038-0. Epub 2012 Nov 30. Cancer Chemother Pharmacol. 2013. PMID: 23196640 Clinical Trial.
Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.
Kümler I, Sørensen PG, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. Kümler I, et al. Among authors: nielsen dl, nielsen pg. Cancer Chemother Pharmacol. 2019 Jan;83(1):169-178. doi: 10.1007/s00280-018-3720-7. Epub 2018 Nov 8. Cancer Chemother Pharmacol. 2019. PMID: 30406838 Free PMC article. Clinical Trial.
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.
Kümler I, Eefsen RL, Sørensen PG, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. Kümler I, et al. Among authors: nielsen dl, nielsen pg. Cancer Chemother Pharmacol. 2019 Aug;84(2):441-446. doi: 10.1007/s00280-019-03819-0. Epub 2019 Apr 4. Cancer Chemother Pharmacol. 2019. PMID: 30949758
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
187 results